[Relationship between estrogen receptor gene Px haplotype and the effect of calcium and soy isoflavone supplementation on bone mineral density of Chinese postmenopausal women].Zhonghua Yu Fang Yi Xue Za Zhi. 2008 May; 42(5):329-34.ZY
To investigate the relationship between estrogen receptor gene Px haplotype and the effect of calcium and soy isoflavone supplementation on bone mineral density (BMD) of Chinese postmenopausal women.
It was a randomly controlling test for 12 months. The Pvu II and Xba I polymorphisms of ER-alpha gene were detected by using restriction fragment length polymorphisms (RFLP) in 691 Chinese postmenopausal women, aged 45-65 years. In 497 carriers of definitive Pvu II-Xba I haplotype, 93 subjects were chosen randomly. BMD was measured by dual energy X-ray absorptiometry (DXEA). According to BMD T score in any skeleton site of 81 subjects at baseline, 29 subjects with T > or = -1.5 were grouped into observation group, and 52 subjects with T < -1.5 were randomly assigned into two intervention groups and received either a 100 mg soy isoflavone and 440 mg Ca and 100 IU VD supplement/d (n = 26) or 440 mg Ca and 100 IU VD supplement/d (n = 26). BMD of the whole body, lumber (L2-L4), and hip were measured at baseline and after 12 months.
After one year fellow-up, the BMD at L2-L4, femur neck site and whole body were significantly decreased as compared with those of baseline (P < 0.05, change percent of BMD as follows: -3.31%, -3.09%, -1.88%) in observation group, and the whole body BMD was significantly lower at 12 month than that at baseline in subjects with Px haplotype (percent change was -2.44%, P < 0.05), but no difference was found in subjects without Px haplotype. Whole body and femur neck BMD were significantly decreased in both Ca group and Ca + soy isoflavone group, but no significant difference of change percent between two groups. There were no significant changes in L2-L4 and trochanter BMD irrespective of treatment. ER-alpha Px haplotype had no effect on the changes in BMD in both Ca group and Ca + soy isoflavone group.
The rate of bone loss in Chinese postmenopausal women seems to haverelation to ER Px haplotype. Calcium supplementation for 1 year might lower the bone loss rate, but soy isoflavone supplementation for 1 year had notshowu no effects. The effect of supplementation had no relationship with ER Px haplotype.